Skip to main content
Back to Top

 

Jeanne Mandelblatt, MD, MPH

Credentials

Associate Director for Population Sciences, Lombardi Comprehensive Cancer CenterDirector, Division of Health Outcomes and Health Behaviors, Department of OncologyProfessor of Oncology and Medicine, Georgetown UniversityCoordinating Principal Investigator, CISNET Breast Cancer Group

Biography

Jeanne Mandelblatt is Associate Director for Population Sciences at the Lombardi Comprehensive Cancer Center. She also serves as the Director of the Division of Health Outcomes and Health Behaviors in the Department of Oncology. She is also a Professor of Oncology and Medicine and a Master of Public Health (MPH). Dr. Mandelblatt is interested in the biology of breast cancer and aging and is a geriatrician with training in cancer epidemiology and health services research. She is involved in the Aging Initiative of the Georgetown University Center for Population and Health. In addition, she was the primary force behind winning a $1 million gift from Avon to develop a comprehensive breast cancer clinic (The Capital Breast Cancer Center) for low-income residents in the southeast section of Washington, DC.Her research focuses on age and race/ethnicity related disparities in cancer care and outcomes. She has conducted more than a decade of research on issues in access to screening and treatment for breast and cervical cancer among elderly black women. She has also conducted research to demonstrate that mammography continues to save lives for elderly women of all ages, even in the presence of co-existent medical conditions.She is presently Principal Investigator of the AHCPR-funded PORT evaluating the patterns of care, outcomes, and cost-effectiveness of treatment of early stage disease among newly diagnosed elderly black and white women. She is leading two NIH-funded grants to examine cost-effectiveness of cancer screening in elderly, and elderly African-American women. A major accomplishment of her screening work was the inclusion of triennial Pap smears as the first early detection effort covered for Medicare beneficiaries.